No Data
BAIYUNSHAN PH (600332.SH): Amoxicillin and Clavulanate Potassium Dry Suspension has passed the consistency evaluation for generic drugs.
BAIYUNSHAN PH (600332.SH) announced that recently, the company's subsidiary Guangzhou BAIYUNSHAN PH Pharmaceutical Group Co., Ltd...
BAIYUNSHAN PH (00874): Liu Juyuan resigns as an executive director of the Ninth Board of Directors.
BAIYUNSHAN PH (00874) issued an announcement that the company's Board of Directors received a document submitted by Liu Juye on January 21, 2025...
Express News | Guangzhou Baiyunshan Pharmaceutical - Received Resignation From Liu Juyan as Executive Director of 9TH Session
BAIYUNSHAN PH (600332.SH): Elect Li Xiaojun as Director.
On January 21, Gelonghui reports that BAIYUNSHAN PH (600332.SH) announced that it convened the 19th meeting of the 9th Board of Directors on January 21, 2025, where it reviewed and approved the proposal regarding the election of the chairman of the 9th Board of Directors and the proposal regarding the election of the legal representative of the company. It was agreed to elect Executive Director Mr. Li Xiaojun as the chairman of the 9th Board of Directors, with a term starting from the date of election until the expiration of the term of the 9th Board of Directors; at the same time, according to the relevant provisions of the Articles of Association, the company's legal representative will be changed to Mr. Li Xiaojun. The company will complete the corresponding corporate registration information change as soon as possible.
Express News | Guangzhou Baiyunshan Pharmaceutical Says Board Agrees to Elect Li Xiaojun as Chairman
China Securities Co.,Ltd.: Policy encouragement + new technology promotion + overseas opportunities create new chances, maintaining a bullish outlook on the Innovative Drugs industry.
National policies encourage the development of Innovative Drugs, new technologies promote the rapid growth of the Industry, new opportunities arise for going overseas, and there is a continuous Bullish outlook for the Innovative Drugs Industry.
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down